Skip to main content

Table 1 Comparison of patients with metastatic colorectal cancer who achieved chemotherapy induced neutropenia (CIN) ≥ grade 2 CTCAE (EXPOSED – CIN-1-Month positive) as compared to those who did NOT have ≥ grade 2 CIN at the 1-month mark – (Referent – CIN-1-Month – ve) after starting treatment with TAS-102

From: Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

 

Variable

Patients with CIN-1-month N (%) (CIN-1 month positive)

Patients without CIN-1-month N (%) (CIN-1 month - ve)

P-value

1

Number

69 (46.3 %)

80 (53.7 %)

 

2

Females

29 (42.0 %)

42 (52.5 %)

0.20

3

Older Adults (Age > 65 years)

39 (56.5 %)

39 (48.8 %)

0.34

4

EAP (versus validation cohort)

33 (47.8 %)

37 (46.3 %)

0.85

5

Primary site Colon (vs. Rectal)

38 (55.1 %)

50 (62.5 %)

0.36

6

RAS-wild type

32 (46.4 %)

41 (51.3 %)

0.56

7

High Baseline CEA (> 55 ng/ml)

24 (34.7 %)

43 (53.8 %)

0.02*

8

Higher Baseline Neutrophil Count (> 4300/mm3)

19 (27.5 %)

55 (68.8 %)

<0.0001**

9

Overall disease control rate (DCR)

32 (49.2 %)

28 (37.8 %)

0.18

-Partial Response (PR)

-4 (6.1 %)

-1 (1.3 %)

-Stable Disease (SD)

-28 (43.1 %)

-27 (36.5 %)

-Progressive Disease (PD)

-33 (50.8 %)

-46 (62.2 %)

10

Progression Free Survival (PFS) in months (95 % CI2)

3.0 (2.3–3.6)

2.4 (1.9–2.9)

0.0096*

11

Overall Survival (OS) in months (95 % CI2)

14.0 (11.2-NR1)

5.6 (4.7–8.1)

<0.0001**

  1. 1NR not reached, 2CI confidence interval
  2. *p-value < 0.05
  3. **p-value < 0.001